
|Videos|November 29, 2018
Assessing Barriers to Oral Oncolytic Adherence
Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
Advertisement
From financial toxicity to lifestyle, there are many factors that could prevent patients from consistently taking their medication. Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
There’s no way a checklist can be as comprehensive as it needs to be to cover all possible influential factors, Oubre said. Having a conversation with patients is the best way to get a clear understanding of what their barriers might be and how to overcome them.
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer
2
Thoracic Oncology Advances and Toxicity Management
3
ASCO Releases First Living Guideline for Recurrent Ovarian Cancer Care
4
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
5























































